Home > Insider Trading > Filing (0001209191-23-023696)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1496323	Igm Biosciences Inc.	IGMS	Pharmaceutical Preparations (2834)	770349194

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1857434	George Gauthier	C/O Igm Biosciences, Inc. 325 E. Middlefield Road Mountain View CA 94043	Chief Commercial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-04-04	16,250	$0.00	34,813	No	4	A	Direct
Common Stock	Disposition	2023-04-05	935	$12.60	33,878	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2023-04-04	32,500	$0.00	32,500	$12.86

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
32,500		2033-04-04	No	4	A	Direct

Footnotes

These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. One-fourth of the RSUs shall vest on March 12, 2024 and each one-year anniversary thereafter, provided that the Reporting Person remains a service provider through each vesting date.
The sale reported by the Reporting Person was effected pursuant to a Rule 10b5-1 trading plan, entered into on December 29, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
1/48 of the shares subject to the option shall vest on April 12, 2023 and each month thereafter, provided that the Reporting Person remains a service provider through each vesting date.